Characteristic | Viral suppression by week | Crude Odds Ratio | Adjusted Odds Ratio | ||
---|---|---|---|---|---|
Baseline n (%) | 24 Weeks n (%) | 48 Weeks n (%) | OR (95% CI) | aOR (95% CI) | |
Monitoring arm | |||||
Immunologic | 46 (65) | 43 (68) | 46 (70) | Ref | Ref a |
Immunologic & Virologic | 46 (65) | 43 (65) | 47 (69) | 0.88 (0.46; 1.69) | 1.06 (0.47; 2.42) |
ARV Change∫ | |||||
No | 78 (66) | 77 (69) | Ref | Ref | |
Yes | 8 (80) | 16 (70) | 1.52 (0.59; 3.89) | 0.85 (0.27; 2.73) | |
Study Site | |||||
Mulago | 43 (61) | 38 (59) | 43 (63) | Ref | Ref b |
Nsambya | 49 (68) | 48 (74) | 50 (76) | 1.56 (0.82; 2.99) | 0.70 (0.25; 1.96) |
Sex | |||||
Female | 39 (64) | 34 (63) | 41 (69) | Ref | Ref c |
Male | 53 (65) | 52 (69) | 52 (69) | 1.12 (0.58; 2.15) | 1.01 (0.45; 2.26) |
WHO Stage | |||||
1 | 16 (73) | 12 (63) | 14 (66) | Ref | Ref d |
2 | 38 (67) | 40 (78) | 40 (74) | 1.14 (0.42; 3.09) | 0.63 (0.17; 2.26) |
3 | 33 (61) | 31 (61) | 33 (66) | 0.74 (0.28; 1.98) | 0.49 (0.14; 1.66) |
4 | 5 (56) | 3 (38) | 6 (67) | 0.55 (0.13; 2.32) | 0.28 (0.05; 1.63) |
NVP Exposure | |||||
Yes | 27 (51) | 28 (55) | 28 (56) | Ref | Ref e |
No | 56 (74) | 47 (72) | 55 (77) | 2.61 (1.31; 5.21)** | 2.75 (1.19; 6.37)** |
Unknown | 9 (69) | 11 (85) | 10 (77) | 2.92 (0.83; 10.32) | |
In utero ART | |||||
Yes | 27 (63) | 25 (60) | 24 (57) | Ref | Ref f |
No | 51 (62) | 47 (65) | 54 (72) | 1.37 (0.67; 2.77) | 1.20 (0.53; 2.74) |
Unknown | 14 (82) | 24 (93) | 15 (88) | 5.10 (1.26; 20.61)* | – |
Age (years) | 1.01 (0.90; 1.16) | 1.19 (0.97; 1.48)g | |||
ART duration (years) | 0.70 (0.56; 0.88)** | 0.67 (0.49; 0.91)h* | |||
CD%/cell count | 1.03 (0.99; 1.07) | 1.09 (1.04; 1.15)i* | |||
Log (Absolute CD4) | 2.82 (1.39, 5.69)** | 2.75 (1.17; 15.18)i* | |||
BMI-for-age Z: | 0.79 (0.61; 1.01) | 0.85 (0.62; 1.15)j | |||
Weight-for-age Z: | 0.96 (0.73; 1.28) | 1.11 (0.75; 1.64)j | |||
Height-for-age Z: | 1.21 (0.91; 1.61) | 1.33 (0.91; 1.93)j |